Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 2, 2003, Pages 362-370

  Ellis, Rodney J ^a,b   Vertocnik, Amy ^b   Kim, Edward ^b   Zhou, Hang ^b   Young, Benjamin ^b   Sodee, Bruce ^b   Fu, Pingfu ^b   Beddar, Sam ^b   Colussi, Valdir ^b   Spirnak, John P ^c   Dinchman, Kurt H ^c   Resnick, Martin ^b   Kinsella, Timothy J ^b  

^a AULTMAN HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; ProstaScint; Prostate

Indexed keywords

IMPLANTS (SURGICAL); PATIENT TREATMENT; PROBABILITY; RADIOLOGY;

BRACHYTHERAPY;

ONCOLOGY;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CALCULATION; CANCER GRADING; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; EVALUATION; FOLLOW UP; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIOIMMUNOASSAY; RADIOLOGICAL PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; WESTERN HEMISPHERE;

EID: 0041381213     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00588-1     Document Type: Article

References (23)

1. Cancer facts and figures-2003. 2003;American Cancer Society, Atlanta, GA.
2. 125I brachytherapy. Int J Radiat Oncol Biol Phys. 51:2001;31-40.
3. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
4. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 46:2000;839-850.
5. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 47:2000;1261-1266.
6. National Cancer Institute SEER report on prostate cancer, 2001. http://Seer.cancer.gov.
7. Wright G.L., Haley C., Beckett M.L., et al. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1:1995;18-28.
8. Ellis R.J., Kim E.Y., Conant R., et al. Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys. 49:2001;1281-1286.
9. Sodee D.B., Ellis R.J., Samueals M.A., et al. Prostate cancer and prostate bed SPECT imaging with Prostascint Semiquantitative correlation with prostatic biopsy results . Prostate. 37:1998;140-148.
10. Lyons J.A., Kupelian P.A., Mohan D.A., et al. Importance of radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 55:2000;85-90.
11. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response Results of the MD Anderson phase II randomized trial . Int J Radiat Oncol Biol Phys. 53:2002;1097-1105.
12. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer Early toxicity and biochemical outcome in 772 patients . Int J Radiat Oncol Biol Phys. 53:2002;1111-1116.
13. Zelefsky M.J., Leibel S., Gaudin P., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
14. Ellis R.J., Sodee D.B., Spirnak J.P., et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys. 48:2000;683-687.
15. Kwok Y., Dibiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent 125I brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys. 53:2002;588-594.
16. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
17. Merrick G.S., Butler W.M., Galbreath R.W., et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 51:2001;41-48.
18. Grado G.L., Larson T.R., Balch C.S., et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 42:1998;289-298.
19. Ragde H., Korb L., Elgamal A., et al. Modern prostate brachytherapy Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up . Cancer. 89:2000;135-141.
20. Merrick G.S., Butler W.M., Lief J.H., et al. Biochemical outcome for hormone-naïve intermediate risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Brachytherapy. 1:2002;95-101.
21. DiBiase S.J., Hosseinzadeh K., Gullapalli R.P., et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 52:2002;429-438.
22. Zelefsky M.J., Cohen G., Zakian K., et al. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. Cancer J. 6:(4):2000;249-255. (abstract).
23. Stock R.G., Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol. 13:(6):1997;454-460.